Truist Securities expressed confidence in its latest note that Merck will be able to navigate the upcoming Gardasil headwinds ...

Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in patients with advanced, unresectable, or metastatic pheochromocytoma and ...

Shares of Merck & Co. Inc. MRK shed 1.32% to $99.65 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.11% to 5,842.91 ...

Of 23 enrolled patients, 10 in cohort 1 and 10 in cohort 2 received lete-cel. Investigator-assessed ORR was 20% (95% CI, 2.5 to 55.6) and 40% (95% CI ... The overall response rate per RECIST v1.1 by ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.81 per share of the company’s common ...

Those drugs generated $2.7 billion and $1 billion worldwide ... in 2023 and $21.6 billion through the first nine months of 2024, demonstrating the challenge ahead for Merck as it works to grow ...